These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 38862093)
1. Comparison of genomic profiling of patient-matched primary colorectal and surgical resected distant metastatic (stage IV) colorectal carcinoma for drug actionability. Jan YH; Lu CT; Lam AK Hum Pathol; 2024 Jul; 149():21-28. PubMed ID: 38862093 [TBL] [Abstract][Full Text] [Related]
2. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing. Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406 [TBL] [Abstract][Full Text] [Related]
4. The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing. Zou SM; Li WH; Wang WM; Li WB; Shi SS; Ying JM; Lyu N J Cancer Res Clin Oncol; 2018 Nov; 144(11):2149-2159. PubMed ID: 30171333 [TBL] [Abstract][Full Text] [Related]
5. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected. Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E; Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676 [TBL] [Abstract][Full Text] [Related]
6. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889 [TBL] [Abstract][Full Text] [Related]
7. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients. Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758 [TBL] [Abstract][Full Text] [Related]
8. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081 [TBL] [Abstract][Full Text] [Related]
9. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644 [TBL] [Abstract][Full Text] [Related]
10. Biomarker alterations associated with distinct patterns of metastatic spread in colorectal cancer. Michl M; Taverna F; Kumbrink J; Schiergens TS; Heinemann V; Engel J; Kirchner T; Neumann J Virchows Arch; 2021 Apr; 478(4):695-705. PubMed ID: 33300106 [TBL] [Abstract][Full Text] [Related]
11. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients. Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504 [TBL] [Abstract][Full Text] [Related]
12. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer. Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer. van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686 [TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles. Vignot S; Lefebvre C; Frampton GM; Meurice G; Yelensky R; Palmer G; Capron F; Lazar V; Hannoun L; Miller VA; André F; Stephens PJ; Soria JC; Spano JP Eur J Cancer; 2015 May; 51(7):791-9. PubMed ID: 25797355 [TBL] [Abstract][Full Text] [Related]
16. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183 [TBL] [Abstract][Full Text] [Related]
17. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Schrock AB; Ouyang C; Sandhu J; Sokol E; Jin D; Ross JS; Miller VA; Lim D; Amanam I; Chao J; Catenacci D; Cho M; Braiteh F; Klempner SJ; Ali SM; Fakih M Ann Oncol; 2019 Jul; 30(7):1096-1103. PubMed ID: 31038663 [TBL] [Abstract][Full Text] [Related]
18. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of liquid biopsies for detection of emerging mutated genes in metastatic colorectal cancer. Furuki H; Yamada T; Takahashi G; Iwai T; Koizumi M; Shinji S; Yokoyama Y; Takeda K; Taniai N; Uchida E Eur J Surg Oncol; 2018 Jul; 44(7):975-982. PubMed ID: 29452859 [TBL] [Abstract][Full Text] [Related]
20. Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing. Mogensen MB; Rossing M; Østrup O; Larsen PN; Heiberg Engel PJ; Jørgensen LN; Hogdall EV; Eriksen J; Ibsen P; Jess P; Grauslund M; Nielsen HJ; Nielsen FC; Vainer B; Osterlind K BMC Cancer; 2018 Jul; 18(1):752. PubMed ID: 30029640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]